Group 1 - IGC Pharma, Inc. reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of +50.00% [1] - The company posted revenues of $0.33 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.45%, compared to revenues of $0.29 million a year ago [2] - IGC Pharma has surpassed consensus EPS estimates three times over the last four quarters [2] Group 2 - The stock has underperformed the market, losing about 7.7% since the beginning of the year, while the S&P 500 gained 4.4% [3] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $0.33 million, and -$0.11 on revenues of $1.5 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is in the top 33% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Company Overview - Nektar Therapeutics (NKTR) shares increased by 12.1% to close at $9.54, following a significant volume of trading, contrasting with a 13.2% loss over the previous four weeks [1] - The rise in stock price is attributed to growing investor optimism regarding the phase IIb REZOLVE-AD study of rezpegaldesleukin for moderate-to-severe atopic dermatitis [1] Financial Expectations - Nektar is projected to report a quarterly loss of $2.53 per share, reflecting a year-over-year increase of 32.5% [2] - Expected revenues for the upcoming report are $10.78 million, which is a decrease of 54.1% compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Nektar has been revised 10.5% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - Monitoring Nektar's stock is advised to see if the recent price increase can sustain and lead to further strength [3] Industry Context - Nektar operates within the Zacks Medical - Drugs industry, which includes other companies such as Indivior PLC (INDV) [4] - Indivior's stock closed 0.4% lower at $13.95, but has seen a return of 24.4% over the past month [4] - Indivior's consensus EPS estimate remains unchanged at $0.25, representing a decline of 43.2% from the previous year [5]

Revenue Performance - Net revenue for the three months ended March 31, 2025, decreased by $18 million, or 6%, to $266 million compared to $284 million in the prior year period[97] - U.S. net revenue decreased by 8% to $222 million in Q1 2025 from $241 million in Q1 2024, primarily due to increased competition and lower pricing for SUBOXONE Film[98] - SUBLOCADE accounted for 66% of net revenue in Q1 2025, down from 63% in Q1 2024, while other buprenorphine-based products accounted for 32% in Q1 2025, down from 33% in Q1 2024[93] Financial Metrics - Gross margin decreased to 83% in Q1 2025 from 87% in Q1 2024, reflecting unfavorable manufacturing variances in the current period[103] - Net cash provided by operating activities was $75 million in Q1 2025, an increase of $112 million compared to a net cash used of $37 million in Q1 2024[111] - Total cash and investments increased to $400 million as of March 31, 2025, from $347 million as of December 31, 2024[109] Expenses and Investments - Research and development expenses decreased by $5 million, or 19%, to $22 million in Q1 2025, as the company refocused its development pipeline[105] - The company expects capital expenditures of approximately $50 million to $70 million in 2025, primarily for the SUBLOCADE suite at the Raleigh Manufacturing Facility[113] - Capital expenditures for the three months ended March 31, 2025, were $5 million, primarily for the expansion of the Raleigh Manufacturing Facility[118] Liabilities and Cash Needs - Current liabilities exceed current assets by $122 million, and total liabilities exceed total assets by $285 million[115] - The company anticipates meeting its cash needs for at least the next twelve months through existing cash, operations, and debt[116] - The company has a focus on litigation settlement payments and debt repayments as part of its cash requirements[119] Regulatory and Development Updates - The FDA approved label changes for SUBLOCADE on February 24, 2025, allowing for a rapid initiation protocol and alternative injection sites[94] - The INDV-2000 Phase 2 proof of concept study's last subject visit is now expected in the first half of 2026, delayed from late 2025 due to lower than expected enrollment[121] Contingent Liabilities and Market Risk - The company is subject to contingent liabilities as described in its financial statements[117] - No material changes in market risk have occurred since the last annual report[124] - As of March 31, 2025, no material changes to contractual obligations have occurred beyond the ordinary course of business[119] Sales Volume and Liquidity - The company needs to sustain sales volume performance to maintain necessary liquidity in the near term[116] - The company is investing in capital expenditures to support its manufacturing capabilities[118]

Financial Data and Key Metrics Changes - Total net revenue in Q1 2025 declined by 6% year on year, amounting to $266 million, primarily due to intensified competition from generic film providers and the discontinuation of PERSERIS [6][16] - Non-GAAP adjusted operating profit increased by 10% compared to the previous year, reflecting lower expenses that partially offset the reduction in total net revenue [11] - Non-GAAP adjusted net income decreased by 11% year on year to $51 million, influenced by revenue dynamics and increased net finance expenses [25] Business Line Data and Key Metrics Changes - SUBLOCADE revenue declined by 2% year on year, with U.S. performance impacted by funding challenges in the justice system, although there was growth in the organized health system channel [7][18] - SUBLOCADE's net revenue outside the U.S. grew by 8% to $13 million, indicating strong performance in international markets [18] - Suboxone Film's average market share in the U.S. was approximately 15%, down by three percentage points from the previous year, reflecting ongoing pricing pressures [21] Market Data and Key Metrics Changes - U.S. net revenue declined by 8% year on year, while the rest of the world saw a 3% increase in reported revenue [16][17] - Approximately 170,700 patients were treated in the U.S. over the past twelve months, representing a 14% increase year on year [9] Company Strategy and Development Direction - The company is focused on reinvesting approximately $50 million of gross savings into SUBLOCADE and its pipeline, while maintaining financial flexibility and disciplined capital allocation [12][28] - Management anticipates that SUBLOCADE's net revenue performance will improve in the second half of the year due to commercial investments and label updates [10][19] - The company is actively monitoring the evolving funding landscape in the justice system, with expectations for growth as new systems are added and funding challenges are addressed [56][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering full-year 2025 guidance, despite current challenges, and noted that the opioid epidemic remains a bipartisan issue with strong governmental support [35][29] - The company expects to see stabilization in the competitive landscape for SUBLOCADE, with new patient share remaining stable at over 70% [10][45] - Management highlighted the importance of generating real-world evidence to support the use of OpV and the potential for growth in the long-acting injectable category [84][86] Other Important Information - The company ended Q1 with gross cash and investments of $400 million, higher than expected due to a decrease in net working capital [27] - The court granted the company's motion to dismiss U.S. shareholder claims, with a 30-day period for plaintiffs to amend their complaint [29] Q&A Session Summary Question: Any proposals regarding Medicaid funding that might change the outlook? - Management is closely monitoring the situation, noting that it remains a bipartisan issue with strong governmental support for opioid treatment [35] Question: When will SUBLOCADE return to growth? - Management expects growth to accelerate in the organized health system channel through marketing initiatives and label enhancements [44] Question: Expectations for CGS dynamics and funding improvements? - Management anticipates growth in criminal justice accounts through the year, with potential funding improvements from various interventions [56][60] Question: Impact of pricing and destocking for SUBLOCADE in Q1? - There was some destocking in Q1, but overall pricing remained stable [63] Question: Expectations around the marketing campaign and new label? - Management sees significant opportunity for awareness and growth in the long-acting injectable category, with early indicators showing positive impact from marketing efforts [68] Question: Further pricing pressure for Suboxone? - Management expects continued price erosion due to competitive pressures, particularly with the introduction of additional generics [76][78] Question: Progress on alternate sites of care for SUBLOCADE? - The company has made progress with eight partners and is working to expand access to alternate sites of care [105]

[Indivior Q1 2025 Earnings Release](index=1&type=section&id=Indivior%20Q1%202025%20Earnings%20Release) The company reports Q1 2025 results, strategic updates, and reaffirms full-year guidance amid market challenges and pipeline developments [Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) Q1 2025 net revenue declined 6% to $266 million due to generic competition and temporary SUBLOCADE headwinds **Q1 2025 Financial Summary (vs. Q1 2024)** | Unaudited, $m | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | **Net Revenue** | 266 | 284 | (6)% | | **Operating Income** | 66 | 75 | (12)% | | **Net Income** | 47 | 61 | (23)% | | **Diluted EPS ($)** | $ 0.38 | $ 0.45 | (15)% | | **Non-GAAP Operating Income** | 69 | 76 | (10)% | | **Non-GAAP Net Income** | 51 | 57 | (11)% | | **Non-GAAP Diluted EPS ($)** | $ 0.41 | $ 0.42 | (2)% | - SUBLOCADE net revenue declined modestly by **2% YoY to $176m**, attributed to dispense volume decline in the justice system channel from near-term funding gaps, which offset solid growth in the organized health system (OHS) channel[3](index=3&type=chunk) - U.S. SUBOXONE Film net revenue declined due to intensified competition from generic film providers, with its share of the oral buprenorphine market falling to **14.8% in Q1 2025** from 17.5% in Q1 2024[10](index=10&type=chunk) - **CEO Mark Crossley announced he will be stepping down** in the upcoming month, with Joe Ciaffoni set to lead the company's next chapter[2](index=2&type=chunk) [Business & Strategic Updates](index=2&type=section&id=Business%20%26%20Strategic%20Updates) The company advanced SUBLOCADE with FDA label changes but faced a pipeline delay for INDV-2000 - The FDA approved key label changes for SUBLOCADE in February 2025 to improve treatment flexibility and experience[7](index=7&type=chunk) - - **Rapid Initiation Protocol:** Allows SUBLOCADE initiation after a single transmucosal buprenorphine dose and a one-hour observation period - - **Alternative Injection Sites:** Administration is now approved for the abdomen, thigh, buttock, or back of the upper arm[10](index=10&type=chunk) - - **INDV-2000 (OREXIN-1 Antagonist):** The estimated last subject visit for the Phase 2 study is now expected in H1 2026, a delay from the previous Q4 2025 estimate, due to slower-than-expected subject enrollment - - **INDV-6001 (3-Month Buprenorphine LAI):** The Phase 2 PK study is on track, with the last subject visit expected in Q4 2025[10](index=10&type=chunk) - The fourth **$100m share repurchase program was completed** on January 31, 2025, under which 9,415,726 ordinary shares were repurchased and canceled[7](index=7&type=chunk) [FY 2025 Financial Guidance](index=2&type=section&id=FY%202025%20Financial%20Guidance) The company reaffirms its full-year 2025 guidance, projecting net revenue of $955 million to $1,025 million - The Company's guidance for FY 2025 under U.S. GAAP remains unchanged[8](index=8&type=chunk) **FY 2025 Guidance** | Metric | FY 2025 Guidance | | :--- | :--- | | **Net Revenue (NR)** | $955m to $1,025m | | **SUBLOCADE NR** | $725m to $765m | | **OPVEE NR** | $10m to $15m | | **Non-GAAP Gross Margin** | Low to mid-80s % range | | **Non-GAAP SG&A** | ($525m) to ($535m) | | **Non-GAAP R&D** | ($85m) to ($90m) | | **Non-GAAP Operating Income** | $185m to $225m | - Guidance assumes no material changes to Medicaid eligibility, federal funding levels, or significant impacts from U.S. or retaliatory tariffs[9](index=9&type=chunk) [Q1 2025 Financial Performance Review](index=4&type=section&id=Q1%202025%20Financial%20Performance%20Review) Q1 net revenue fell 6% to $266 million, with lower gross margin partially offset by reduced operating expenses [Net Revenue](index=4&type=section&id=Net%20Revenue) Total net revenue declined 6% to $266 million, driven by an 8% drop in U.S. revenue from competitive pressures **Q1 2025 Net Revenue Breakdown ($m)** | Region/Product | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Total U.S.** | 222 | 241 | | *SUBLOCADE (U.S.)* | 163 | 168 | | *PERSERIS* | 4 | 11 | | **Rest of World** | 44 | 42 | | **Total Net Revenue** | **266** | **284** | - The decrease in U.S. NR was primarily driven by the decline in SUBOXONE Film due to intensified generic competition and the discontinuation of PERSERIS promotion in July 2024[14](index=14&type=chunk) [Profitability and Expenses](index=4&type=section&id=Profitability%20and%20Expenses) Gross margin fell to 83% while SG&A and R&D expenses decreased, resulting in a net income of $47 million - Gross margin declined to **83% from 87% YoY**, primarily due to favorable manufacturing variances for SUBLOCADE inventory sold in Q1 2024[16](index=16&type=chunk) - Non-GAAP SG&A expense **decreased 8% to $130m**, reflecting benefits from streamlining actions, including the discontinuation of PERSERIS[17](index=17&type=chunk) - R&D expense **decreased 19% to $22m**, reflecting actions to refocus the development pipeline on Phase 2 OUD assets[18](index=18&type=chunk) - Net interest expense increased to **$7m from $2m in Q1 2024**, reflecting new borrowing secured in Q4 2024[20](index=20&type=chunk) [Balance Sheet and Cash Flow](index=5&type=section&id=Balance%20Sheet%20and%20Cash%20Flow) Cash and investments rose to $400 million, boosted by strong operating cash flow from a temporary rebate delay - Cash and investments **increased by $53m** during the quarter to a total of **$400m** at March 31, 2025[25](index=25&type=chunk) - The cash increase was primarily due to cash from operations and a **c. $100m reduction in net working capital** from the late receipt of government rebate invoices, partially offset by $65m in litigation settlement payments[25](index=25&type=chunk) - Cash provided by operating activities was **$75m in Q1 2025**, a significant improvement from the $37m cash used in operating activities in Q1 2024[26](index=26&type=chunk) [Revision to Previously Issued Financial Statements](index=5&type=section&id=Revision%20to%20Previously%20Issued%20Financial%20Statements) The company corrected its accrual methodology for the U.S. Branded Fee, revising prior SG&A expense figures - The company revised its financial statements to correct the accrual methodology for the U.S. 'Branded Fee'[28](index=28&type=chunk) - This resulted in correcting an immaterial overstatement of SG&A by **$6m in 2024, $4m in 2023, $4m in 2022, and $2m before 2022**, with a cumulative impact of $16m to Accounts Payable and Accrued Expenses at Dec 31, 2024[28](index=28&type=chunk) [Consolidated Financial Statements (Unaudited)](index=9&type=section&id=Consolidated%20Financial%20Statements%20(Unaudited)) This section presents the unaudited Q1 2025 statements of operations, balance sheets, and cash flows [Consolidated Statements of Operations](index=9&type=section&id=Consolidated%20statements%20of%20operations) **Consolidated Statements of Operations (Three Months Ended March 31)** | (In millions) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net revenue | $ 266 | $ 284 | | Gross profit | 221 | 246 | | Operating income | 66 | 75 | | Income before income taxes | 59 | 73 | | Net income | $ 47 | $ 61 | | Diluted EPS | $ 0.38 | $ 0.45 | [Consolidated Balance Sheets](index=10&type=section&id=Consolidated%20balance%20sheets) **Consolidated Balance Sheets (in millions)** | | Mar 31, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Total current assets** | $ 883 | $ 827 | | **Total assets** | **$ 1,375** | **$ 1,316** | | **Total current liabilities** | $ 1,005 | $ 924 | | **Total liabilities** | **$ 1,660** | **$ 1,652** | | **Total shareholders' deficit** | **$ (285)** | **$ (337)** | [Consolidated Statements of Cash Flows](index=11&type=section&id=Consolidated%20statements%20of%20cash%20flows) **Consolidated Statements of Cash Flows (Three Months Ended March 31, in millions)** | | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $ 75 | $ (37) | | Net cash (used in) provided by investing activities | $ (5) | $ 25 | | Net cash used in financing activities | $ (17) | $ (56) | | **Net increase (decrease) in cash and cash equivalents** | **$ 53** | **$ (68)** | | **Cash and cash equivalents at end of period** | **$ 372** | **$ 248** | [Selected Revenue and Expense Information](index=12&type=section&id=Selected%20revenue%20and%20expense%20information) **Q1 Net Revenue by Product ($m)** | Three Months Ended March 31, | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **US:** | | | | SUBLOCADE | $ 163 | $ 168 | | Sublingual & other | 54 | 63 | | PERSERIS | 4 | 11 | | **Total U.S.** | **222** | **241** | | **Rest of World** | **44** | **42** | | **Net revenue** | **$ 266** | **$ 284** | [Reconciliation of GAAP to non-GAAP Financial Information](index=13&type=section&id=Reconciliation%20of%20GAAP%20to%20non-GAAP%20financial%20information) **GAAP to Non-GAAP Reconciliation Summary (Q1 2025, $m)** | Measure | GAAP | Adjustments | Non-GAAP | | :--- | :--- | :--- | :--- | | **Operating Income** | $66 | $3 | $69 | | **Net Income** | $47 | $3 | $51 | | **Diluted EPS** | $0.38 | | $0.41 | [Appendix](index=5&type=section&id=Appendix) This section provides supplementary details, including investor contacts, non-GAAP definitions, and safe harbor statements